Intraocular Pressure-Regulated Early Genes Targeting for Glaucoma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current glaucoma treatments primarily focus on reducing intraocular pressure (IOP), but they often fail to prevent continued retinal ganglion cell (RGC) death and optic nerve deterioration, as the molecular links between high IOP and RGC apoptosis remain unclear, and existing therapies do not effectively address the underlying causes of glaucoma progression.
Innovation Solution
A method involving compositions of small interfering RNAs, antisense oligonucleotides, and neutralizing antibodies that inhibit the expression or activity of up-regulated intraocular pressure-regulated early genes (IPREGs), such as α2 macroglobulin, to treat glaucoma by preventing RGC death and chronic ocular degeneration, potentially combined with IOP-normalizing drugs like betaxolol.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stress or pressure
If IOP-reducing pharmacological treatment is applied, then intraocular pressure is normalized, but retinal ganglion cell death and optic nerve deterioration continue
Solution Approach 1:
The patent extracts and targets specific molecular mediators (IPREGs such as α2 macroglobulin, HSP27, and heat shock factor 1) that are upregulated in response to ocular hypertension and directly mediate RGC apoptosis. By specifically inhibiting these molecular pathways rather than merely reducing IOP, the treatment addresses the root cause of RGC death that persists despite pressure normalization.
Solution Approach 2:
The patent employs gene silencing technologies (antisense oligonucleotides, RNA interference) to preemptively inhibit the expression of IPREGs before they can fully execute their pro-apoptotic functions. This preliminary molecular intervention prevents the cascade of events leading to RGC death, even when IOP remains elevated or normalizes fluctuating.
2Stress or pressure
If current glaucoma therapies are used, then IOP is reduced to near normal levels, but the molecular causes of glaucoma progression are not addressed
Solution Approach 1:
The patent introduces molecular intermediaries (antisense oligonucleotides, small interfering RNAs) that specifically bind to and silence IPREG mRNA transcripts. These intermediaries bridge the gap between IOP reduction and direct molecular pathway inhibition, allowing precise targeting of apoptotic signaling cascades without requiring complex surgical interventions or invasive procedures.
3Productivity
If high IOP exposure continues, then RGC apoptosis progresses at a constant rate, but the exact biochemical triggering events remain unknown
Solution Approach 1:
The patent converts the harmful upregulation of IPREGs in response to ocular hypertension into a beneficial therapeutic target. By identifying and silencing these pressure-responsive genes that normally mediate cell death, the treatment transforms the pathological molecular response into a specific intervention point, allowing prevention of RGC apoptosis while maintaining the body's natural IOP regulation mechanisms.
Data Source
Figure 1A~1B
Figure 2
Figure 3
AI summary
The present invention relates to methods to treat glaucoma and glaucoma-related conditions through the regulation of changes in gene expression that are mediated by high intraocular pressure. Glaucoma, retinal ganglion cell (RGC) death and chronic ocular hypertension are treated using pharmaceutical compositions which comprise substances that inhibit the expression or activity of intraocular pressure-regulated early genes (IPREGs) or their gene products that are up-regulated by high intraocular pressure and/or which increase the expression or activity of IPREGs or their gene products that are down-regulated by high intraocular pressure. The invention also relates to methods of identifying an IPREG and methods to test for chronic ocular degeneration and the onset of RGC stress in an individual by measuring the expression level of IPREG proteins.